Search results
May 7, 2024 · AbbVie pharmaceuticals combines advanced science with expertise to make strides in drug and treatment discovery, making a remarkable impact on people's lives.
It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74. [2] The company's primary product is Humira (adalimumab) ($14 billion in 2023 revenues, 27 percent of total), administered via injection.
May 7, 2024 · AbbVie discovers and delivers innovative medicines and solutions that enhance people’s lives.
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues...
AbbVie formed a new kind of enterprise – a biopharmaceutical company – with the stability, global scale, resources and commercial capabilities of a pharmaceutical company and the focus and culture of a biotech. Since the beginning, our mission hasn't wavered.
Focused on results, dedicated to innovations. AbbVie is a global biopharmaceutical company with focus and capabilities to address some of the world's greatest health challenges. AbbVie discovers, develops, and commercializes advanced therapies that have an impact on people's lives.
Find the latest AbbVie Inc. (ABBV) stock quote, history, news and other vital information to help you with your stock trading and investing.
Search for information or submit an inquiry to the AbbVie Medical Information team. Begin your search by selecting a product, after which you may select from relevant categories. If you are unable to find documents with the search tool, please fill out the ‘submit inquiry’ form below.
Apr 18, 2022 · AbbVie’s mission is to discover and deliver innovative medicines and solutions that address complex health issues and enhance people's lives.
Feb 12, 2024 · AbbVie Completes Acquisition of ImmunoGen. Adds flagship antibody-drug conjugate (ADC) ELAHERE® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC) to AbbVie's portfolio. ImmunoGen's pipeline complements AbbVie's existing oncology pipeline with potential to be transformative ...
